PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. - Wikidata - awgldk - TriplyDB

PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.

PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.

http://www.wikidata.org/entity/Q34433549

about

Progress in adjuvant chemotherapy for breast cancer: an overview Gene expression analysis in RA: towards personalized medicine Advances in the Molecular Analysis of Breast Cancer: Pathway Toward Personalized Medicine The promise of multi-omics and clinical data integration to identify and target personalized healthcare approaches in autism spectrum disorders Current treatment of early breast cancer: adjuvant and neoadjuvant therapy Quantification of HER family receptors in breast cancer Exosomes-mediate microRNAs transfer in breast cancer chemoresistance regulation Signatures of breast cancer metastasis at a glance Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer.Human breast cancer metastases to the brain display GABAergic properties in the neural niche.The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.Initiation of metastatic breast carcinoma by targeting of the ductal epithelium with adenovirus-cre: a novel transgenic mouse model of breast cancer.Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression.The challenge of triple negative breast cancers ID2 predicts poor prognosis in breast cancer, especially in triple-negative breast cancer, and inhibits E-cadherin expression Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes Dissecting the Biological Heterogeneity within Hormone Receptor Positive HER2 Negative Breast Cancer by Gene Expression Markers Identifies Indolent Tumors within Late Stage Disease.Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)Predicting response and survival in chemotherapy-treated triple-negative breast cancer.Age-specific changes in intrinsic breast cancer subtypes: a focus on older women Tracking progesterone receptor-mediated actions in breast cancer Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples.iGPSe: a visual analytic system for integrative genomic based cancer patient stratification.Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner.Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression.Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer.Development and verification of the PAM50-based Prosigna breast cancer gene signature assay Genomic aberrations in young and elderly breast cancer patients.Study design requirements for RNA sequencing-based breast cancer diagnostics Breastfeeding, PAM50 tumor subtype, and breast cancer prognosis and survival.CrossLink: a novel method for cross-condition classification of cancer subtypes Associations between sociodemographic and clinicopathological factors and breast cancer subtypes in a population-based study.Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.

P2860

Q26798078-8BF73B88-CB28-4B3D-9BD0-75DB02902570 Q26825706-FBE656CF-E742-4F64-B242-48C1B0E137BB Q27001994-B6679179-7989-48B9-B8D4-488879EC6DAE Q27005952-28B202AA-9188-4A6A-BA11-4C7198BF1978 Q27011658-CBEB34A2-E847-488F-9653-9BA6E0A035F7 Q27015506-FE5C3B24-D996-4EBE-9E0E-43DD49680FB4 Q28066991-B13869FE-5959-412C-AC37-6FF0FA71B528 Q28071451-4A5CEB8F-31E6-455D-B03B-56026163B282 Q28077637-2F452938-ABB4-459E-A013-2E96EAA28EC2 Q28085062-A90CDDB8-8FB1-41C9-AE15-18C68BEA4608 Q30377229-C992AFBC-0EB1-466B-A7A1-9008A124AB3D Q30491493-B68B04A6-0E9C-4273-9CF0-4793BD86792B Q30569512-F7216550-18FA-43D8-BF9E-3B58A3DD6922 Q30978083-E44A90B6-93D1-420A-B885-B79B9DAC91EC Q33573884-28F0DC50-8782-465E-A20A-4A61F2B23BBA Q33635061-D460CA15-B5F5-420F-8FFB-DA50ADD19393 Q33669007-AAAF0E8F-8253-4C9D-9E2D-F0C8B587CE15 Q33774570-DAE97AC6-AD96-4932-8B5B-CD0ACE674747 Q33800620-F04778B7-1A52-4201-9F39-34BB279ECB97 Q33874621-8FBA25CE-D4D9-4073-90E1-5D0EC7493629 Q33892778-58287301-2020-4406-90F5-DEAE2D11ACA2 Q33897072-DDE12674-9AF0-4082-94B8-16471C0C5740 Q33915057-497697D2-5492-4CA2-A569-C4FFF9B43767 Q33927000-174207E3-84C8-4404-9C7F-1342CC19DAE6 Q34169294-904B512B-7448-4D72-892A-9DBEBBA0388E Q34354538-B223BE45-CE16-41F8-BC34-0916DE795466 Q34359310-C2892C16-9F9A-4322-B083-40AB68B630E7 Q34388848-66C6E6FA-06DB-4D8B-B200-185B619BD2F5 Q34468621-99F87AA7-8F81-40F3-A619-7CD3EA9EE688 Q34486150-38FF68F2-9623-48D6-8242-417BD16D0278 Q35021758-95A79036-453F-4D58-AC16-9CF4952A54AE Q35492620-1604488E-490A-4CA0-A41A-C5D1474174B6 Q35496344-34A59990-BBB3-4AA2-9C28-7F4E1BA7B1FE Q35752868-6A1E5579-6BD0-4CAA-930C-B04EDE2D8CF0 Q35807554-44515ED8-A056-4324-83FE-1587D37FF3F4 Q35910164-2476830D-2DDF-4AC0-AFD6-97112CEDD204 Q36009818-3A4D39EB-9772-4EBB-98D9-B8581AA7F66C Q36111302-AB9E8EC6-2BB0-4AD4-8930-4F9118F40F2E Q36235990-D127F9A4-EB45-44F2-BF9B-41C0404AADC1 Q36383626-06A621E4-825D-49E7-836A-4F5CDAFD6F78

P2860

PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.

http://www.wikidata.org/entity/Q34433549

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

PAM50 breast cancer subtyping ...... rd clinical molecular markers.

@ast

PAM50 breast cancer subtyping ...... rd clinical molecular markers.

@en

PAM50 breast cancer subtyping ...... rd clinical molecular markers.

@nl

type

label

PAM50 breast cancer subtyping ...... rd clinical molecular markers.

@ast

PAM50 breast cancer subtyping ...... rd clinical molecular markers.

@en

PAM50 breast cancer subtyping ...... rd clinical molecular markers.

@nl

prefLabel

PAM50 breast cancer subtyping ...... rd clinical molecular markers.

@ast

PAM50 breast cancer subtyping ...... rd clinical molecular markers.

@en

PAM50 breast cancer subtyping ...... rd clinical molecular markers.

@nl

P1433

Q34433549-2AF9D4E6-08CB-4F0E-AE45-A2FCD26A23C9

P1476

Q34433549-81C99A9C-40EC-41FC-A442-F2EFCD75A2F6

P2093

Q34433549-0CD69F00-0EEA-4F4D-994A-6E92B87E6574

Q34433549-10028AD9-7029-40E5-83FE-17FC55DA8C2C

Q34433549-1115F955-23B8-4DFB-9E17-7F0104C72BD5

Q34433549-13888821-075E-4F1F-B556-AC1B5F58CF5E

Q34433549-16B82058-DF83-4112-AA15-32D3E8E00103

Q34433549-24A0EDE7-C46E-4F8C-A313-10F49FAF710D

Q34433549-29C0ABAE-25D1-4AE6-AA45-455EE214129F

Q34433549-2DDF98DE-60BB-49B3-A689-92A4DD92DDE9

Q34433549-449D841B-88E5-4D64-9790-3896CDA14B89

Q34433549-5BEA52E9-AA0A-4797-882D-4052ED6322B1

P2860

Q34433549-02E4CABE-958C-47C3-A906-4BFC8AF4F498

Q34433549-050D2D3D-D7B4-4713-8A2C-B104213D0471

Q34433549-0E286268-33C8-44D0-9533-C4DC4E3C8F3B

Q34433549-13C0391E-01CB-4B8B-9CB0-20FDD966D868

Q34433549-1DAC991F-3E6E-4FF8-A72B-C4715598958E

Q34433549-1F882310-9319-4308-86E0-8B775AFD50C4

Q34433549-213C3F09-51D5-472E-9845-BF78E672F9E5

Q34433549-25050C83-395E-4DE7-B5BE-8D4B3EC8CC5E

Q34433549-25F7D831-8104-4B79-9B21-1871E11C97F0

Q34433549-25FF7DD7-157B-4767-83FE-3F3C1D7B6B83

P2888

Q34433549-B1FD08E7-5284-4997-ADFB-FF10F7FC69E8

P304

Q34433549-8C200F0F-3A66-40A0-9A85-8ED5C1C9227C

P31

Q34433549-7CA82B8A-D2B3-4A7B-8444-DC9692C136BF

P356

Q34433549-267A7E5E-3A32-4306-90E2-946C4ADC216D

P478

Q34433549-B5D1E3F4-4433-4C81-B4A8-65FDEF141BE1

P50

Q34433549-20AF3E50-7564-44B7-A2C5-3F2427E6A155

Q34433549-23E8FFB2-313E-4A8A-B32A-D6CF87DB1970

Q34433549-45B3117A-5F16-4266-8E6F-9EDD83F780F4

Q34433549-8021FD05-8680-4A78-8F84-8E8F37057B68

Q34433549-9E294F36-B272-4BDB-B80C-34A7995DD940

Q34433549-C69312D4-3A9C-4E49-887E-82AD80B1BE7A

P577

Q34433549-CF76C061-18E2-4B68-AB67-3CBD0317EEB8

P5875

Q34433549-AEE8B760-A64F-455E-9928-1171ADDDBAD9

P6179

Q34433549-FD4F335D-6CDA-4182-BBC6-F6EA2645B931

P698

Q34433549-EE192D7A-1912-4CBD-AFCA-DDF2C88FE2D7

P932

Q34433549-9357BDBE-1C36-430F-8EA2-7E5AAC98F34F

P356

P1433

BMC Medical Genomics

P1476

PAM50 breast cancer subtyping ...... ard clinical molecular markers

@en

P2093

Antonio Antón

http://www.w3.org/2001/XMLSchema#string

Blanca Munárriz

http://www.w3.org/2001/XMLSchema#string

Bradley Lyons

http://www.w3.org/2001/XMLSchema#string

Carole A Davis

http://www.w3.org/2001/XMLSchema#string

Christiane Fauron

http://www.w3.org/2001/XMLSchema#string

Daniel Anderson

http://www.w3.org/2001/XMLSchema#string

David Wall

http://www.w3.org/2001/XMLSchema#string

Emilio Alba

http://www.w3.org/2001/XMLSchema#string

Eva Carrasco

http://www.w3.org/2001/XMLSchema#string

Inge J Stijleman

http://www.w3.org/2001/XMLSchema#string

P2860

Cluster analysis and display of genome-wide expression patterns

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

A gene-expression signature as a predictor of survival in breast cancer

Molecular portraits of human breast tumours

Repeated observation of breast tumor subtypes in independent gene expression data sets

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Direct multiplexed measurement of gene expression with color-coded probe pairs

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

Diagnosis of multiple cancer types by shrunken centroids of gene expression

Supervised risk predictor of breast cancer based on intrinsic subtypes

P2888

P304

44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1755-8794-5-44

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Charles M. Perou

Kenneth Boucher

P577

2012-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232085434

http://www.w3.org/2001/XMLSchema#string

P6179

1021824566

http://www.w3.org/2001/XMLSchema#string

P698

23035882

http://www.w3.org/2001/XMLSchema#string

P932

3487945

http://www.w3.org/2001/XMLSchema#string